Keryx Biopharmaceuticals Inc (KERX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Keryx Biopharmaceuticals Inc (KERX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012281
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company’s lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based phosphate binder, which helps lower the amount of phosphate in human blood. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric (ferric citrate coordination complex). The company has subsidiaries and offices in Israel, the US, and the UK. Keryx is headquartered in New York, the US.

Keryx Biopharmaceuticals Inc (KERX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 11
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 12
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 16
Keryx BioPharma Completes Underwritten Public Offering Of US$33 Million 18
Debt Offering 20
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Acquisition 21
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc – Key Competitors 22
Keryx Biopharmaceuticals Inc – Key Employees 23
Keryx Biopharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 07, 2017: Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results 25
Jul 27, 2017: Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance 27
May 04, 2017: Keryx Biopharmaceuticals Announces First Quarter 2017 Financial Results 29
Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 31
Nov 09, 2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update 33
Aug 01, 2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results 35
Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results 36
Feb 25, 2016: Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results 38
Corporate Communications 40
Sep 13, 2017: Keryx Biopharmaceuticals Announces Changes to its Board of Directors 40
Jun 21, 2016: Keryx Biopharmaceuticals Appoints Two New Board Members 41
Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Keryx Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Keryx Biopharma Plans to Raise up to USD75 Million in Public Offering of Shares 11
Keryx Biopharma Prices Public Offering of Shares for USD110 Million 12
Keryx Biopharma Completes Public Offering Of Shares For US$115 Million 14
Keryx Biopharma Completes Public Offering Of Shares For US$80 Million 16
Keryx BioPharma Completes Underwritten Public Offering Of US$33 Million 18
Keryx Biopharma to Raise USD125 Million in Private Placement of Notes Due 2020 20
Baupost Acquires 10.7% Stake In Keryx Biopharma 21
Keryx Biopharmaceuticals Inc, Key Competitors 22
Keryx Biopharmaceuticals Inc, Key Employees 23
Keryx Biopharmaceuticals Inc, Subsidiaries 24

★海外企業調査レポート[Keryx Biopharmaceuticals Inc (KERX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Atrion Corp (ATRI):企業の財務・戦略的SWOT分析
    Summary Atrion Corp (Atrion) is a medical device company that develops, manufactures and supplies surgical equipment and components. The company offers cardiovascular products, fluid delivery products and ophthalmology products. Its products comprise cardiac surgery vacuum relief valves, silicon ves …
  • Geberit Ag:企業の戦略・SWOT・財務分析
    Geberit Ag - Strategy, SWOT and Corporate Finance Report Summary Geberit Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Vital Images Inc:企業の戦略的SWOT分析
    Vital Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Renesas Electronics Corp (6723):企業の財務・戦略的SWOT分析
    Renesas Electronics Corp (6723) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Alstom SA (ALO):企業の財務・戦略的SWOT分析
    Alstom SA (ALO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • The Bank of East Asia, Limited:企業のM&A・事業提携・投資動向
    The Bank of East Asia, Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bank of East Asia, Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Punjab National Bank:企業の戦略・SWOT・財務分析
    Punjab National Bank - Strategy, SWOT and Corporate Finance Report Summary Punjab National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sudarshan Chemical Industries Ltd (SUDARSCHEM):企業の財務・戦略的SWOT分析
    Sudarshan Chemical Industries Ltd (SUDARSCHEM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報
    Summary CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of …
  • Calithera Biosciences Inc (CALA):企業の財務・戦略的SWOT分析
    Summary Calithera Biosciences Inc (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminas …
  • Nippon Chemi-Con Corporation (6997):企業の財務・戦略的SWOT分析
    Nippon Chemi-Con Corporation (6997) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Entersoft SA (ENTER):企業の財務・戦略的SWOT分析
    Entersoft SA (ENTER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Enmax Corp:企業の戦略的SWOT分析
    Enmax Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Baltimore Gas and Electric Company:発電所・企業SWOT分析
    Baltimore Gas and Electric Company - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information o …
  • Euronet Worldwide, Inc.:企業の戦略・SWOT・財務分析
    Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • NeuroMetrix Inc (NURO)-医療機器分野:企業M&A・提携分析
    Summary NeuroMetrix Inc (NeuroMetrix) is a medical device company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, SENSUS pain therapy device, NC-stat DPNChe …
  • Serco Inc:企業の戦略的SWOT分析
    Serco Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Armada Hoffler Properties Inc:企業の戦略・SWOT・財務分析
    Armada Hoffler Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Armada Hoffler Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • GIZEH Raucherbedarf GmbH:企業の戦略的SWOT分析
    GIZEH Raucherbedarf GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Aurora National Life Assurance Company:企業の戦略・SWOT・財務情報
    Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report Summary Aurora National Life Assurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆